Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Teva
Daiichi Sankyo
Deloitte
Fish and Richardson
Accenture
Chubb
Cerilliant
Queensland Health
Merck

Generated: February 23, 2018

DrugPatentWatch Database Preview

Salix Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for SALIX PHARMS INC, and what generic alternatives to SALIX PHARMS INC drugs are available?

SALIX PHARMS INC has one approved drug.

There are seven US patents protecting SALIX PHARMS INC drugs and there have been three Paragraph IV challenges on SALIX PHARMS INC drugs in the past three years.

There are sixty-eight patent family members on SALIX PHARMS INC drugs in thirty-one countries.

Summary for Salix Pharms Inc
International Patents:68
US Patents:7
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Salix Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Salix Pharms Inc RELISTOR methylnaltrexone bromide TABLET;ORAL 208271-001 Jul 19, 2016 RX Yes Yes 8,524,276 ➤ Sign Up Y ➤ Sign Up
Salix Pharms Inc RELISTOR methylnaltrexone bromide TABLET;ORAL 208271-001 Jul 19, 2016 RX Yes Yes 9,492,445 ➤ Sign Up Y ➤ Sign Up
Salix Pharms Inc RELISTOR methylnaltrexone bromide TABLET;ORAL 208271-001 Jul 19, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up
Salix Pharms Inc RELISTOR methylnaltrexone bromide TABLET;ORAL 208271-001 Jul 19, 2016 RX Yes Yes 8,420,663 ➤ Sign Up ➤ Sign Up
Salix Pharms Inc RELISTOR methylnaltrexone bromide TABLET;ORAL 208271-001 Jul 19, 2016 RX Yes Yes 9,724,343 ➤ Sign Up Y ➤ Sign Up
Salix Pharms Inc RELISTOR methylnaltrexone bromide TABLET;ORAL 208271-001 Jul 19, 2016 RX Yes Yes 8,956,651 ➤ Sign Up Y ➤ Sign Up
Salix Pharms Inc RELISTOR methylnaltrexone bromide TABLET;ORAL 208271-001 Jul 19, 2016 RX Yes Yes 9,180,125 ➤ Sign Up Y ➤ Sign Up
Salix Pharms Inc RELISTOR methylnaltrexone bromide TABLET;ORAL 208271-001 Jul 19, 2016 RX Yes Yes 9,314,461 ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for SALIX PHARMS INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 150 mg ➤ Subscribe 9/6/2016
➤ Subscribe Injection 8 mg/0.4 mL ➤ Subscribe 9/8/2015
➤ Subscribe Injection 12 mg/0.6 mL ➤ Subscribe 7/22/2015

Non-Orange Book US Patents for Salix Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,247,425 Peripheral opioid receptor antagonists and uses thereof ➤ Sign Up
8,455,644 Peripheral opioid receptor antagonists and uses thereof ➤ Sign Up
8,822,490 Peripheral opioid receptor antagonists and uses thereof ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Salix Pharms Inc Drugs

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Fish and Richardson
Chubb
Moodys
Cerilliant
Julphar
Harvard Business School
Accenture
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot